The Precision Medicine Webinar Series

Summary

In an increasingly competitive market, a data-driven and timely commercialization strategy is crucial to enable successful therapy and biomarker adoption.
The precision medicine industry is now in its fourth decade of clinical impact with significant progress continuing to be made, including the discovery of new biomarkers, treatments and testing methods. Despite technological and clinical advances, studies show that effective biomarker-driven approaches are still widely underutilized.

The perceived costs associated with launching new therapies are rising, placing a significant strain on resources available to pharma and biotechs. Diagnostic testing remains under-supported with many healthcare facilities lacking comprehensive genetic testing capabilities. This, coupled with a knowledge gap among physicians, can result in a significant proportion of eligible patients being lost along the treatment pathway.